Humana

Dr. Shantanu Nundy appointed as Chief Medical Officer at Humana, joining from health navigation firm Accolade. Nundy brings FDA AI advisory experience, teaching background, World Bank work, and clinical practice.

Leadership read: A change at the top rarely stays at the top. Humana's move reshapes the layer beneath it in Human Resources as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-08-20 · context →

James 'J.P.' Holland, former Johns Hopkins executive, appointed to lead Humana's Medicaid business effective immediately. Part of broader leadership transition announced in late 2025.

Leadership read: A change at the top rarely stays at the top. Humana's move reshapes the layer beneath it in Human Resources as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-08-11 · context →

Humana divests its interest in end-of-life care provider Gentiva (valued at $900M) to undisclosed investor group

Leadership read: Humana's divestiture of Gentiva commits the company to a structurally narrower operating model. Holding a $900M stake in an end-of-life care platform gave Humana a vertical integration play, ownership of care delivery alongside insurance risk, that relatively few payers had pursued at scale. Selling that position doesn't simply remove an asset; it removes the internal capability and data loop that integrated ownership was supposed to provide. The transaction signals a deliberate retreat from the care-delivery ownership thesis back toward a payer-only posture, likely under pressure from regulatory scrutiny of private capital in hospice and palliative care. This is one of twelve M&A signals we have tracked across sectors in the last 90 days, though the Humana-Gentiva transaction is the most consequential in the healthcare vertical within that set. The relevant parallel isn't Grant Thornton or Nuveen, it's the broader pattern of corporate sellers separating operating assets from investment portfolios under regulatory and public-sentiment pressure. That dynamic is accelerating specifically in healthcare, where scrutiny of private ownership in end-of-life settings has become a live political and regulatory issue. Across payer and health-services companies navigating similar portfolio simplification, the functional pressure concentrates in two areas: regulatory affairs leadership capable of managing divestiture-linked compliance obligations across state licensing regimes, and strategic finance and corporate development capability to reposition balance sheet capacity after a major asset exit. The market is moving toward operators who can manage post-divestiture integration risk as cleanly as acquisition integration.

curated · 2026-06-11 · context →